Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt (2022 - 2025)

Axsome Therapeutics' Total Debt history spans 4 years, with the latest figure at $187.7 million for Q4 2025.

  • For Q4 2025, Total Debt fell 0.66% year-over-year to $187.7 million; the TTM value through Dec 2025 reached $187.7 million, down 0.66%, while the annual FY2025 figure was $187.7 million, 0.66% down from the prior year.
  • Total Debt for Q4 2025 was $187.7 million at Axsome Therapeutics, up from $127.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $190.0 million in Q1 2025 and bottomed at $49.3 million in Q1 2022.
  • The 4-year median for Total Debt is $183.6 million (2023), against an average of $152.2 million.
  • The largest annual shift saw Total Debt surged 211.51% in 2023 before it plummeted 32.32% in 2025.
  • A 4-year view of Total Debt shows it stood at $100.2 million in 2022, then soared by 84.18% to $184.5 million in 2023, then increased by 2.45% to $189.0 million in 2024, then decreased by 0.66% to $187.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Total Debt are $187.7 million (Q4 2025), $127.3 million (Q3 2025), and $126.8 million (Q2 2025).